Azoximer bromide
Expression error: Unexpected < operator.Expression error: Unexpected < operator.Expression error: Unexpected < operator.
 | |
| Clinical data | |
|---|---|
| Synonyms | Polyoxidonium, Synpol |
| ATC code | |
| Pharmacokinetic data | |
| Bioavailability | up to 89% |
| Elimination half-life | 25.4 hours (intravenous routes) |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}} |
| Chemical and physical data | |
| Formula | [[C8H15BrN2O2]x[C6H12N2O]y]n |
| Molar mass | 60000–100000 g/mol |
Azoximer bromide is a macromolecular compound with high-molecular weight and not proved immunomodulating activity. It is using in CIS countries for treatment and prophylaxis of diseases connected with damage of immune system. It is a N-oxidized polyethylene–piperazine derivative. Azoximer bromide is sold under the trade name Polyoxidonium.
Polyoxidonium is registered in US Patent-5503830 from 1996,[1][2][3] in the Russian Federation from 1996, under registration number 96/302/9, FS 42-3906-00.[4]
References
- ↑ http://www.google.com/patents/about?id=s9cfAAAAEBAJ&dq=US+5503830
- ↑ http://www.wikipatents.com/US-Patent-5503830/compounds-having-immunostimulating-activity-and-methods-of-use-thereof[dead link]
- ↑ "Compounds for the Prevention and Treatment of Helminth Infections".
- ↑ State Scientific Centre of Russian federation, Immunological Institute of Russian Federation Health Resort, CLINICAL ASPECTS OF USE OF IMMUNOMODULATOR POLYOXIDONIUM, Methodical handbook for doctors issued by State Scientific Centre of Russian Federation – Immunological Institute of Russian Federation Health Resort Moscow – 2003
